PCSK9 and metabolic syndrome: 4)PCSK9 inhibitors: While PCSK9 inhibitors (eg, evolocumab, alirocumab) are not recommended for most primary prevention patients, they can be considered in very-high-risk individuals (eg, those with a CAC score >1,000 AU or severe dyslipidemia).